MARKET

KPRX

KPRX

KIORA PHARMACEUTICALS INC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7100
-0.0400
-5.33%
After Hours: 0.7500 +0.04 +5.63% 17:42 01/27 EST
OPEN
0.7500
PREV CLOSE
0.7500
HIGH
0.7692
LOW
0.6500
VOLUME
277.63K
TURNOVER
--
52 WEEK HIGH
7.85
52 WEEK LOW
0.6300
MARKET CAP
8.98M
P/E (TTM)
-0.4658
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Avinger (NASDAQ:AVGR) stock moved upwards by 9.7% to $0.34 during Friday's after-market session. This security traded at a volume of 1.2 million shares come close, making up 60.0% of its average volume over the last 100 days. The company's market c...
Benzinga · 01/14 21:31
Kiora Pharmaceuticals to Provide 2022 Business Outlook at the H.C. Wainwright Bioconnect Virtual Conference
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) will participate in the H.C. Wainwright Bioconnect Virtual Conference January 10-13, 2022. Brian M Strem, Ph.D., President and Chief Executive Officer, will provide an outlook for the busines and its pipeline of t...
Benzinga · 01/05 12:08
61 Biggest Movers From Yesterday
Gainers Genprex, Inc. (NASDAQ: GNPX) shares surged 167.2% to settle at $3.50 on Monday. The FDA granted Fast Track Designation for Genprex’s lead drug candidate, Reqorsa Immunogene combination therapy.
Benzinga · 01/04 10:06
Genprex, Creative Medical Technology leads healthcare gainers; Applied Therapeutics, Nutriband among major losers
Gainers: Genprex (NASDAQ:GNPX) +68%, Creative Medical Technology (NASDAQ:CELZ) +52%, Pear Therapeutics (NASDAQ:PEAR) +33%, GBS (NASDAQ:GBS) +30%, PainReform (NASDAQ:PRFX) +15%. Losers: Applied Therapeutics (NASDAQ:APLT) -30%, Nutriband (NTRBW) -24%, AgeX T...
Seekingalpha · 01/03 16:00
BBIO, SYTA and IMTE among mid-day movers
Gainers: Nutriband (NASDAQ:NTRB) +188%. Siyata Mobile (NASDAQ:SYTA) +36%. Medalist Diversified (NASDAQ:MDRR) +26%. uCloudlink (NASDAQ:UCL) +23%. Xeris Biopharma (NASDAQ:XERS) +22%. Biodesix (NASDAQ:BDSX) +22%. Dingdong Limited (NYSE:DDL) +18%. Lava Therape...
Seekingalpha · 12/31/2021 17:22
Nutriband soars among healthcare gainers, Star Equity takes top loser tag
Gainers: Nutriband NTRB +184%. Nutriband (NTRBW) +134%. Xeris Biopharma (NASDAQ:XERS) +20%. Lava Therapeutics (NASDAQ:LVTX) +16%. Biodesix (NASDAQ:BDSX) +14%. Losers: Star Equity (NASDAQ:STRR) -17%. Kiora Pharmaceuticals (NASDAQ:KPRX) -14%. Spruce Bioscien...
Seekingalpha · 12/31/2021 16:00
Nutriband tops healthcare gainers; Star Equity among losers
Gainers: Nutriband NTRB +181%. Nutriband NTRBW +127%. Xeris Biopharma XERS +19%. Biodesix (NASDAQ:BDSX) +15%. Apollo Endosurgery (NASDAQ:APEN) +11%. Losers: Star Equity (NASDAQ:STRR) -17%. Kiora Pharmaceuticals (NASDAQ:KPRX) -16%. Spruce Biosciences. (NASD...
Seekingalpha · 12/31/2021 15:56
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Benzinga · 12/30/2021 13:07
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of KPRX. Analyze the recent business situations of KIORA PHARMACEUTICALS INC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average KPRX stock price target is 8.00 with a high estimate of 15.00 and a low estimate of 2.500.
High15.00
Average8.00
Low2.500
Current 0.7100
EPS
Actual
Estimate
-0.42-0.31-0.21-0.10
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 32
Institutional Holdings: 625.80K
% Owned: 4.95%
Shares Outstanding: 12.65M
TypeInstitutionsShares
Increased
4
247.63K
New
8
177.19K
Decreased
0
0
Sold Out
6
3.60M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.31%
Pharmaceuticals & Medical Research
+0.35%
Key Executives
Chairman/Executive Director
Stephen From
President/Chief Executive Officer/Director
Brian Strem
Chief Financial Officer
Sarah Romano
Executive Vice President
Franz Obermayr
Other
Eric Daniels
Lead Director/Independent Director
Paul Chaney
Independent Director
Kenneth Gayron
Independent Director
David Hollander
Independent Director
Aron Shapiro
Independent Director
Praveen Tyle
No Data
About KPRX
Kiora Pharmaceuticals, Inc., formerly Eyegate Pharmaceuticals, Inc., is a clinical-stage pharmaceutical company. The Company is engaged in developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system. The Company's pipeline consists of three assets including KIO-101, KIO-301, and KIO-201 in early to late-stage development for both common and rare eye diseases. KIO-101, is a non-steroidal, immuno-modulatory and small-molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH). Its KIO-301, is a light-sensitive small molecule that acts as a reversible photoswitch, designed to restore the eyes' ability to perceive and interpret light in visually impaired patients. The Company's KIO-201, which is a form of the natural polymer hyaluronic acid, designed to protect the ocular surface to permit re-epithelialization of the cornea and improve ocular surface integrity.

Webull offers kinds of Kiora Pharmaceuticals Inc stock information, including NASDAQ:KPRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KPRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KPRX stock methods without spending real money on the virtual paper trading platform.